scholarly journals SUDOSCAN in Combination with the Michigan Neuropathy Screening Instrument Is an Effective Tool for Screening Diabetic Peripheral Neuropathy

2021 ◽  
Author(s):  
Tae Jung Oh ◽  
Yoojung Song ◽  
Hak Chul Jang ◽  
Sung Hee Choi
Keyword(s):  
Peripheral Neuropathy ◽  
Diabetic Peripheral Neuropathy ◽  
Screening Instrument ◽  
Michigan Neuropathy Screening Instrument

scholarly journals Comparison of Efficiencies of Michigan Neuropathy Screening Instrument, Neurothesiometer, and Electromyography for Diagnosis of Diabetic Neuropathy

2013 ◽  
Vol 2013 ◽  
pp. 1-7 ◽  
Author(s):  
Turkan Mete ◽  
Yusuf Aydin ◽  
Mustafa Saka ◽  
Halise Cinar Yavuz ◽  
Sule Bilen ◽  
...  
Keyword(s):  
Peripheral Neuropathy ◽  
Physical Examination ◽  
Diabetic Peripheral Neuropathy ◽  
Diabetes Type 2 ◽  
Screening Instrument ◽  
Diabetes Type ◽  
Diabetic Patients ◽  
Patients With Diabetes ◽  
Michigan Neuropathy Screening Instrument

Aim. This study compares the effectiveness of Michigan Neuropathy Screening Instrument (MNSI), neurothesiometer, and electromyography (EMG) in detecting diabetic peripheral neuropathy in patients with diabetes type 2.Materials and Methods. 106 patients with diabetes type 2 treated at the outpatient clinic of Ankara Numune Education and Research Hospital Department of Endocrinology between September 2008 and May 2009 were included in this study. Patients were evaluated by glycemic regulation tests, MNSI (questionnaire and physical examination), EMG (for detecting sensorial and motor defects in right median, ulnar, posterior tibial, and bilateral sural nerves), and neurothesiometer (for detecting alterations in cold and warm sensations as well as vibratory sensations).Results. According to the MNSI score, there was diabetic peripheral neuropathy in 34 (32.1%) patients (score ≥2.5). However, when the patients were evaluated by EMG and neurothesiometer, neurological impairments were detected in 49 (46.2%) and 79 (74.5%) patients, respectively.Conclusion. According to our findings, questionnaires and physical examination often present lower diabetic peripheral neuropathy prevalence. Hence, we recommend that in the evaluation of diabetic patients neurological tests should be used for more accurate results and thus early treatment options to prevent neuropathic complications.

scholarly journals Diabetic Peripheral Neuropathy and Urological Complications in Type 1 Diabetes: Findings From the Epidemiology of Diabetes Interventions and Complications Study

2021 ◽  
Author(s):  
Rodica Pop-Busui ◽  
Barbara H. Braffett ◽  
Hunter Wessells ◽  
William H. Herman ◽  
Catherine L. Martin ◽  
...  
Keyword(s):  
Type 1 Diabetes ◽  
Peripheral Neuropathy ◽  
Diabetic Peripheral Neuropathy ◽  
Diabetes Duration ◽  
Urinary Tract Symptoms ◽  
Urological Complications ◽  
Drinking Status ◽  
Michigan Neuropathy Screening Instrument ◽  
Diabetes Interventions

Objective: <br>To evaluate associations between diabetic peripheral neuropathy (DPN) and urological complications in men and women with type 1 diabetes. <br>ResearchDesignandMethods: <br>Measurements of DPN at EDIC years 1, 13/14 and 17 and urological complications at EDIC year 17 were examined in 635 men (mean age 51.6 yrs, diabetes duration 29.5 yrs) and 371 women (mean age 50.6 yrs and diabetes duration 29.8 yrs) enrolled in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) study. DPN was defined by symptoms, signs and abnormal electrophysiology, or by abnormal Michigan Neuropathy Screening Instrument (MNSI) examination or questionnaire scores. <br>Results: <br>Erectile dysfunction (ED) in combination with lower urinary tract symptoms (LUTS) was reported in 15% of men, and female sexual dysfunction (FSD), LUTS and urinary incontinence (UI) in 16% of women. When controlling for age, drinking status, BMI, depression, DCCT/EDIC time-weighted mean HbA1c, microalbuminuria, hypertension, triglycerides and statin medication use, men with confirmed DPN at EDIC year 13/14 had a higher odds of ED/LUTS at year 17 compared to men without DPN (OR=3.52 95% CI 1.69,7.31). Men with DPN based on abnormal MNSI examination or questionnaire scores had significantly higher odds of ED and LUTS at year 17 than men without DPN at all time points. There were no significant differences in DPN between women reporting both FSD and LUTS/UI compared to those without FSD or LUTS/UI at EDIC year 17. <br>Conclusions: <br>In long-standing T1D, DPN is associated with the later development of urological complications in men. <b></b>

scholarly journals Diabetic peripheral neuropathy and its determinants among patients attending a tertiary health care centre in Mangalore, India

2015 ◽  
Vol 4 (2) ◽  
Author(s):  
Monisha D’Souza ◽  
Vaman Kulkarni ◽  
Unnikrishnan Bhaskaran ◽  
Humam Ahmed ◽  
Hegde Naimish ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Peripheral Neuropathy ◽  
Diabetic Peripheral Neuropathy ◽  
Tertiary Care ◽  
Cross Sectional Study ◽  
Care Hospital ◽  
Health Care Centre ◽  
Cross Sectional ◽  
Michigan Neuropathy Screening Instrument ◽  
Design And Methods

<p><em>Background</em>. The burden of diabetes mellitus (DM) is on the rise especially in developing countries like India. Due to its chronic nature DM tends to cause many debilitating complications and diabetic peripheral neuropathy (DPN) is one of them. The aim of this study is to determine the prevalence of DPN among patients attending a tertiary care hospital and to identify the determinants associated with it. <br /><em>Design and methods</em>. A cross sectional study was conducted in Government Wenlock Hospital, Mangalore (India), during January-February 2014. A total of 208 patients with &gt;5 year duration of DM were asked to respond to the patient history version of Michigan Neuropathy Screening Instrument (MNSI) and examinations were conducted after obtaining consent from them. The statistical analysis was done in terms of descriptive statistics and association between variables was tested using logistic regression test.<br /><em>Results</em>. The prevalence of DPN using the MNSI history version and MNSI examination were found to be 18.3% and 32.2% respectively. The major determinants associated with DPN were found to be male gender (OR: 2.7, CI: 1.4-5.1, P=0.001), smoking (OR: 5.8, CI: 1.9-17.3, P=0.001) and age &gt;40 years (OR: 2.7, CI: 1.2-5.8, P=0.011). <br /><em>Conclusions</em>. The burden of undetected DPN was found to be higher among diabetics, with an especially higher prevalence among males, smokers and those with long standing diabetes mellitus. Interventions in the form of early detection through routine screening, smoking cessation and regular follow up examinations would go a long way in reducing the burden of disability among diabetics and improve their quality of life significantly.</p>

scholarly journals Micronized Palmitoylethanolamide Reduces the Symptoms of Neuropathic Pain in Diabetic Patients

2014 ◽  
Vol 2014 ◽  
pp. 1-5 ◽  
Author(s):  
Chiara Schifilliti ◽  
Lelio Cucinotta ◽  
Viviana Fedele ◽  
Carmela Ingegnosi ◽  
Salvatore Luca ◽  
...  
Keyword(s):  
Neuropathic Pain ◽  
Peripheral Neuropathy ◽  
Symptom Score ◽  
Acid Amide ◽  
Screening Instrument ◽  
Total Symptom Score ◽  
Diabetic Patients ◽  
Serious Adverse Events ◽  
Michigan Neuropathy Screening Instrument ◽  
Pain Symptoms

The present study evaluated the effectiveness of micronized palmitoylethanolamide (PEA-m) treatment in reducing the painful symptoms experienced by diabetic patients with peripheral neuropathy. PEA-m, a fatty acid amide of the N-acylethanolamine family, was administered (300 mg twice daily) to 30 diabetic patients suffering from painful diabetic neuropathy. Before treatment start, after 30 and 60 days the following parameters were assessed: painful symptoms of diabetic peripheral neuropathy using the Michigan Neuropathy Screening instrument; intensity of symptoms characteristic of diabetic neuropathic pain by the Total Symptom Score; and intensity of different subcategories of neuropathic pain by the Neuropathic Pain Symptoms Inventory. Hematological and blood chemistry tests to evaluate metabolic control and safety were also performed. Statistical analysis (ANOVA) indicated a highly significant reduction in pain severity (P<0.0001) and related symptoms (P<0.0001) evaluated by Michigan Neuropathy Screening instrument, Total Symptom Score, and Neuropathic Pain Symptoms Inventory. Hematological and urine analyses did not reveal any alterations associated with PEA-m treatment, and no serious adverse events were reported. These results suggest that PEA-m could be considered as a promising and well-tolerated new treatment for symptomatology experienced by diabetic patients suffering from peripheral neuropathy.

Sign in / Sign up

Export Citation Format

Share Document